2 unchanged sentences
Incorporated by Reference Herein
−Removed: Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp.
−Removed: Current Report on Form 8-K (File No.
−Removed: November 19, 2018
−Removed: Certificate of Amendment to the Amendment and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp.
−Removed: Current Report on Form 8-K (File No.
−Removed: January 14, 2020
−Removed: Certificate of Amendment to the Amendment and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp.
−Removed: Current Report on Form 8-K (File No.
−Removed: January 25, 2023
−Removed: Certificate of Designation of Series D Preferred Stock, dated November 16, 2022.
−Removed: Current Report on Form 8-K (File No.
−Removed: November 16, 2022
−Removed: Form of Series A Common Stock Warrant, dated April 20, 2023.
−Removed: Current Report on Form 8-K (File No.
−Removed: April 20, 2023
−Removed: Form of Series B Common Stock Warrant, dated April 20, 2023.
−Removed: Current Report on Form 8-K (File No.
−Removed: April 20, 2023
−Removed: Form of Existing Warrant Amendment, dated April 28, 2023.
−Removed: Current Report on Form 8-K (File No.
−Removed: April 20, 2023
−Removed: Form of Series A Common Stock Warrant, dated June 2, 2023.
−Removed: Current Report on Form 8-K (File No.
−Removed: Form of Series B Common Stock Warrant, dated June 2, 2023.
−Removed: Current Report on Form 8-K (File No.
−Removed: Form of Pre-funded Common Stock Warrant, dated June 2, 2023.
−Removed: Current Report on Form 8-K (File No.
−Removed: Form of Securities Purchase Agreement, dated April 18, 2023, by and
−Removed: between the Company and each of the Purchasers signatory thereto.
−Removed: Current Report on Form 8-K (File No.
−Removed: April 20, 2023
−Removed: Form of Securities Purchase Agreement, dated May 31, 2023, by and between
−Removed: the Company and each of the Purchasers signatory thereto (Registered Direct Offering).
−Removed: Current Report on Form 8-K (File No.
−Removed: Form of Securities Purchase Agreement, dated May 31, 2023, by and between
−Removed: the Company and each of the Purchasers signatory thereto (PIPE Private Placement).
−Removed: Current Report on Form 8-K (File No.
−Removed: Form of Registration Rights Agreement, dated May 31, 2023, by and between
−Removed: the Company and each of the Purchasers signatory thereto.
−Removed: Current Report on Form 8-K (File No.
+Added: 2020 Phio Pharmaceuticals Corp.
+Added: Long Term Incentive Plan, as amended and restated.
+Added: Form of Nonqualified Stock Option Award under the Company’s 2020 Long Term Incentive Plan.
Sarbanes-Oxley Act Section 302 Certification of Principal Executive Officer and Principal Financial Officer.
7 unchanged sentences
The cover page for this report, formatted in Inline XBRL (included in Exhibit 101).*
+Added: _________________
Filed herewith.
Furnished herewith and not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section or incorporated by reference into any filing under the Securities Act or the Exchange Act.
+Added: Indicates a management contract or compensatory plan or arrangement.
Pursuant to the requirements of the Securities
4 unchanged sentences
(as Principal Executive and Financial Officer)
−Removed: August 10, 2023
+Added: November 9, 2023
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.